Suzy Lim's DAC | INDUSTRY REPORT FEATURING

 

To address gaps in the US healthcare landscape and foster international collaboration, BDMT Global, in collaboration with Fortune Korea, has compiled a list of 40 promising Korean healthcare innovations. This list was selected based on current unmet needs and demands in the US market. The full list of the top 40 is available below, along with a key overview of each innovation's market dynamics and potential to address challenges.

 

 

 

| Cardiology

Current Market Situation | By 2035, approximately 45% of the U.S. population is projected to have some form of cardiovascular disease, with a total cost of nearly $1 trillion. Heart disease remains the leading cause of death in the United States, with approximately 350,000 Americans dying each year from out-of-hospital cardiac arrest alone (only 10% of these individuals survive).

 

At the same time, the shortage of cardiovascular specialists is becoming more serious, and the cardiologist-to-patient ratio is expected to worsen from 1:1087 in 2025 to 1:1700 in 2035.

 

The cardiology market will face additional challenges as funding cuts to the National Institutes of Health (NIH) delay research initiatives for new innovations. Following the Trump administration's announcement, the American Heart Association (AHA) issued an advisory, emphasizing the critical role of the NIH as the world's leading biomedical research institution and cautioning against sudden, unplanned, and disruptive actions that could have unintended consequences for public health.

 

Coreline Soft 
Stage: Already Commercialized
Innovation Overview (▹) Coreline's AVIEW LCS PLUS AI software automates the analysis of lung nodules, chronic obstructive pulmonary disease (COPD), and coronary artery calcifications from chest CT scans. It provides customized reports and features an advanced viewer with 3D visualization capabilities.
Innovation Points (▹▶) AVIEW LCS PLUS supports clinicians by automatically analyzing potentially overlooked nodules, COPD, and coronary artery calcifications, thereby improving diagnostic accuracy and reducing workload.

Daesung Maref Co., Ltd.
Stage: Already commercialized
▹ Pneumatic medical devices effectively utilize pneumatic technology to improve circulation in the body, particularly for the treatment of conditions such as deep vein thrombosis (DVT) and lymphedema.
▹▶ Optimize the cost-quality balance for hospital and home care. Prevent DVT/pulmonary embolism, reduce swelling and pain, and increase venous flow, slashing time and costs by half.

Daesung Maref's official medical device. [Photo = Daesung Maref]
 

Narma
Stage: Already Commercialized
▹ The AED Delivery Drone System is an integrated drone solution designed to deliver an automated external defibrillator (AED) up to 5 km away within three minutes.
▹▶ Outdoor cardiac arrests often go untreated due to limited accessibility to AEDs, which are often located inside buildings. This system addresses this critical gap, increasing the chances of survival when an outdoor cardiac arrest occurs.

 

| Endocrinology Diabetes Center
Current Market Situation | 11.6% of the US population (38.4 million people) has diabetes, and 22.8% of adults with diabetes are undiagnosed. While HbA1c testing is crucial for diagnosis and disease management, many patients miss out on testing due to accessibility and insurance issues. Some insurers are now restricting in-office A1C testing and requiring additional lab visits, leading to delays and increasing the risk of patients skipping appointments.

Continuous glucose monitoring (CGM) is also very useful for managing diabetes, but medications and supplements (such as vitamin C and acetaminophen) can affect the accuracy of certain CGM sensors.

Dr. Adam Stein, an endocrinologist and reviewer, said, “I value data and accuracy. While small and pretty devices are great, if they aren’t accurate, they can cause serious health and medical problems. This is my concern with some home testing products. How accurate are the data they provide? For example, HbA1c levels can become less accurate with age and for other reasons, such as anemia. It’s also frustrating for all of us when there’s a significant discrepancy between CGM data and HbA1c levels.”
 
Bagel Labs
Stage: Clinical Trials
▹ AI-powered digital therapeutics (DTx) that integrate with existing prescription medications to improve treatment outcomes. Their flagship product, DEXULIN, pipeline includes combination therapies for chronic conditions such as obesity, sarcopenia, and osteoarthritis.
▹▶ By embedding DTx into pharmaceuticals, they aim to deliver personalized, patient-centered care with improved efficacy, shorter development time (approximately three years), and cost-effectiveness. It addresses key limitations of traditional drug therapies, including low patient compliance with treatment regimens, limited personalized treatment, and ineffective remote monitoring in chronic disease management.
 
CTBIO 
Phase: Clinical Trials
▹ CTBIO's quantitative lateral flow assay, LampFly Dx™ S, enables affordable, room-temperature stable HbA1c testing with laboratory-grade accuracy (coefficient of variation < 3%). This platform technology can be extended to diagnose diabetes-related complications and various nutritional deficiencies.
▹▶ Making accurate HbA1c testing more affordable and accessible. It improves the measurement precision, room-temperature stability, and self-testing through mobile integration of lateral flow assay (LFA). This contrasts with existing, expensive, traditional testing methods that have lower accuracy, require refrigerated storage and transportation, and require a laboratory visit.

 

Doctor Diary Gluart. [Photo = Doctor Diary]

Doctor Diary
Phase: Already Commercialized
▹ Gluart is a pioneering metabolic health program developed by Doctor Diary, designed to help individuals manage their blood sugar levels and overall well-being. It integrates continuous glucose monitoring (CGM) technology with personalized one-on-one coaching to provide real-time insights into the impact of lifestyle choices on blood sugar levels. 
▹▶ Gluart addresses two key challenges in digital health: the fragmentation of health data and the complexity of the legal framework governing personal health information.
Unlike traditional wellness apps that provide general advice, Gluart personalizes guidance based on an individual's blood sugar response, allowing each user to receive a personalized plan tailored to their unique physiological needs.
 
Elecell 
Phase: Clinical Trials
▹ A self-powered patch for the treatment of chronic wounds, including diabetic foot ulcers, bedsores, burns, and leg ulcers. Elecell's device promotes wound healing through biomimetic electrical stimulation and activates the PI3K/AKT pathway to promote fibroblast proliferation and differentiation. Additionally, Mg/PB nanoparticles eliminate reactive oxygen species that cause chronic wounds while promoting angiogenesis to initiate the healing process.
▹▶ Current treatments on the market primarily focus on preventing infection, reducing inflammation, and managing pain, but do not completely address the wound healing process.
 
Orange Biomed 
Stage: Clinical Trial
▹ OBM rapid A1c is the world's first microfluidic-based glycated hemoglobin (HbA1c) test that aims to revolutionize accessibility to diabetes monitoring. It enables lab-quality A1c testing anywhere with minimal blood sample volume. There is no need for complicated procedures, specialized calibration, or refrigeration.
▹▶ OBM rapid A1c analyzes thousands of individual red blood cells from a single drop of blood in just five minutes, significantly reducing the required sample size and enabling faster, easier testing. Many patients are unable to properly monitor their diabetes due to barriers to laboratory testing. 

 

 

 

| Immunology, Infectious Diseases, Vaccination
Current Market Landscape | Immunology, infectious diseases, and vaccinology are closely interrelated and often interconnected within the broader healthcare ecosystem. Each field faces evolving challenges. For example, HIV testing is a critical component of treatment and prevention, yet it is estimated that approximately 13% of people living with HIV in the United States are unaware of their status.

Dr. Ayana Perkins added, "As rural communities in the United States and around the world face shrinking healthcare infrastructure, limited access to specialists, and declining public health investments, people living with HIV/AIDS are increasingly vulnerable to health disparities. Many of these communities are excluded from the latest research and diagnostic innovations, leading to delayed diagnoses, inadequate monitoring, and preventable health outcomes."

Sepsis will be the third most common cause of death in U.S. hospitals in 2023, affecting approximately 1.7 million Americans annually. Meanwhile, uncertainty persists in vaccine development. In June, the U.S. Department of Health and Human Services announced the cancellation of a more than $700 million contract with Moderna, which aimed to develop, test, and license mRNA vaccines against pandemic-relevant influenza strains, including the H5N1 avian influenza virus.
 
Glory Bio Technologies 
Phase: Market Ready
▹ Glory's GBTsol ICA/CD4 Analyzer enumerates CD4 markers for HIV/AIDS management in low- and middle-income countries through microfiltration.
▹▶ The GBTsol Analyzer enables independent analysis of individual CD markers, such as CD64, CD8, and CD4, and combines marker data to assess patient outcomes such as advanced HIV disease, tuberculosis, and sepsis.
 
Real-Time Medi Check
Stage: Already commercialized
▹ VaxiRigh is an AI-based vaccine safety platform that performs real-time prediction and risk assessment of adverse reactions after vaccination. The system supports automated scanning of syringe unique identifier barcodes and personal QR codes, remote health monitoring, and data linkage with hospital electronic medical records/medical image archiving and communication systems, ensuring an ethical, safe, and transparent vaccination process.
▹▶ VaxiRigh addresses vaccine-related risks that are particularly important in time-sensitive healthcare environments, such as incorrect administration, delayed adverse reaction monitoring, and inefficient post-vaccination follow-up.

Spass
Phase: Clinical Trial
▹ Provides four AI-based solutions. ShockRanger-Hypotension predicts hypotension using arterial blood pressure biosignals, and ShockRanger-Sepsis predicts septic shock using six vital signs. SepsisRanger recommends personalized antibiotics and treatments for sepsis based on biosignals and laboratory data, and InnisVue provides biomarker pattern analysis for cancer diagnosis and treatment.
▹▶ ShockRanger-Hypotension reduces anesthesiologist fatigue, contributing to a decrease in intraoperative mortality. ShockRanger-Sepsis predicts septic shock, and SepsisRanger predicts sepsis, improving patient survival. InnisVue provides precise biomarker-based criteria for targeted therapy selection in breast cancer, enabling more effective and personalized treatment decisions.
 
Lemonex
Phase: Clinical Trials
▹ DegradaBALL-Reducerna is an amRNA platform designed to minimize side effects associated with current lipid nanoparticle-mRNA vaccines by increasing drug retention at the injection site and improving mRNA stability. This process can address issues with ultra-cold distribution networks and supply delays.
▹▶ The DegradaBALL-mRNA system reduces side effects, such as vascular leak syndrome and organ dysfunction, associated with current lipid nanoparticle-mRNA vaccines. DegradaBALL-mRNA reduces these side effects by minimizing systemic drug diffusion and does not induce antigen protein expression outside the injection site. It reduces the frequency of side effects by approximately one-third compared to Moderna's mRNA-LNP vaccine.

 

| Musculoskeletal Disorders
Current Market Landscape | North America, led by the U.S. and Canada, dominates the musculoskeletal disorder treatment market and is expected to maintain its leadership due to the high prevalence of musculoskeletal disorders associated with obesity and unhealthy lifestyles, increasing awareness, and access to advanced treatment options.

Osteoarthritis, the most common form of arthritis in the United States, affects more than 32.5 million adults. Pain caused by osteoarthritis limits physical activity and is a major cause of disability, reducing work capacity in 66% of Americans with osteoarthritis and increasing absenteeism in 21%.

Sarcopenia (age-related muscle loss) is another growing concern, affecting 15 million people in the United States alone, the highest prevalence worldwide. Officially classified as a disease by the Centers for Disease Control and Prevention nine years ago, sarcopenia remains significantly underdiagnosed.
 
Biobytes
Phase: Clinical Trials
▹ MyoTest is an AI-based platform that predicts sarcopenia risk, enabling early detection and personalized intervention. Requiring only grip strength and routine blood tests, it is powered by a clinically validated algorithm using an Institutional Review Board-approved biobank.
▹▶ Sarcopenia is underdiagnosed due to limited access to cost-effective screening tools. MyoTest leverages simple, readily available data in primary care to enable early detection and personalized management.
 
Ensol Biosciences
Phase: Clinical Trials
▹ Developing short-chain peptide drugs that modulate protein-protein interactions for the treatment of degenerative disc disease and osteoarthritis. It is suitable for local administration, has a low immunogenicity, is non-toxic, and has an excellent safety profile.
▹▶ Current treatments for degenerative disc disease and osteoarthritis often rely on systemic medications or invasive procedures, which carry risks of toxicity, immunogenicity, and poor targeting. This innovation enables a localized, low-risk intervention, overcoming major safety and delivery barriers in chronic joint and spinal diseases.
 
Kolon TissueGene
Phase: Clinical Trial
▹ TG-C is a novel allogeneic cell therapy product. It offers a non-surgical, disease-modifying treatment for osteoarthritis and other degenerative joint diseases. It promotes cartilage regeneration and induces M2 macrophage polarization, resulting in an anti-inflammatory response.
▹▶ It provides a non-surgical treatment option and disease-modifying effects for patients with osteoarthritis and other degenerative joint diseases. A single injection provides pain relief and improved joint function. It may reduce long-term dependence on non-steroidal anti-inflammatory drugs, opioids, and corticosteroids.

 

| Neurology
Current Market Situation | A recent study from New York University Langone Health predicts that the number of people with dementia in the United States will double by 2060. One in two Americans is expected to experience cognitive decline after age 55. 

This study projects a rapid increase in the burden of dementia in the United States. Despite the benefits of early screening, several studies show that only one in five older Americans has had a cognitive function test in the past year. This has implications for long-term outcomes.

Neuromuscular diseases comprise hundreds of conditions, affecting 41 out of every 100,000 Americans under the age of 18. Eighty percent of these diseases are hereditary.
 
EN001
cell therapy is being developed to treat neuromuscular and muscular degenerative diseases. Its proprietary biomimetic 
cell culture technology enhances the efficacy of mesenchymal stem cells and shortens production time. Its broad paracrine activity and donor selection strategy ensure therapeutic efficacy and product consistency.
EN001 significantly shortens expansion time with biomimetic culture technology while enhancing stem cell characteristics and therapeutic efficacy. This addresses the high production costs and reduced cell efficacy associated with long culture periods. Its proprietary donor selection platform overcomes the challenges of achieving consistent product quality due to donor-to-donor variation in allogeneic mesenchymal stem cell therapies. It is also one of the most advanced therapeutic candidates in clinical development for Charcot-Marie-Tooth disease, a condition for which there are currently no approved treatments.
 
Koh Young Technology
Stage: Market Ready (FDA/CE/KFDA Approved)
▹ This is a next-generation brain surgery robot for high-precision neurosurgery. Its surgical guide robot and navigation support easy and accurate position registration and real-time tracking. It provides intuitive path guidance and an improved user experience for medical staff.
▹▶ Koh Young Technology's innovations benefit surgeons and patients by reducing surgery time and increasing accuracy. It supports surgical planning and guides the robot to the planned location.

 

MIJ ETEREO TC Square. [Photo = MIJ]

MIJ 
Stage: Already Commercialized
▹ ETEREO TC Square is a Class 2 bone conduction device approved by the Korean Ministry of Food and Drug Safety. It provides personalized tinnitus sound therapy with an open earset and accompanying software. It offers a treatment suitable for comfortable, everyday use and is under development for commercialization in the US by 2025.
▹▶ Traditional tinnitus management in the US has been limited to hearing aids, sound maskers, cognitive therapy, or off-label medications, which have not provided consistent relief. TC Square is a non-invasive, drug-free treatment that can reduce the perceived intensity of tinnitus over time. It alleviates ongoing noise burden and allows patients to self-manage their tinnitus at home. This reduces reliance on clinic visits and ultimately improves the mental health and quality of life of people "learning to live with" tinnitus.

NFC Life Science 
Stage: Already Commercialized
▹ CURICIN PF utilizes neurotechnology to alleviate pain by modulating neurotransmitter activity between nerves and skin cells. Ultra-low molecular weight compounds (less than 500 daltons) derived from microorganisms and natural oils enhance absorption and efficacy. Developed using advanced fermentation and bioconversion technologies, it features a novel compound (OZL-M100) currently under new substance registration.
▹▶ CURICIN PF is a non-opioid, steroid-free pain relief cream. It provides a safe alternative to traditional pain treatments that rely on opioids and steroids, which can weaken the immune system and cause harmful side effects or new health problems. CURICIN PF uses a microbial natural compound (OZL-M100), developed as a safe and effective alternative to steroids. This natural, bioactive compound provides powerful therapeutic effects without suppressing the immune system.
 
Neurogrin
Phase: Clinical Trials
▹ Cerogrin is an electronic device (electropharmaceutical) that "clears brain waste." It is a non-invasive, wearable auricular vagus nerve stimulator that effectively promotes brain cleansing by increasing cerebrospinal fluid flow.
▹▶ Some sedatives are being tested, but they have side effects and cannot be used repeatedly over a long period of time. Neurogreen's wearable medical device, Serogreen, which "clears brain waste," is the best way to improve and restore cognitive function in dementia patients by stimulating glymphatic flow.
 
REMED BRAINSTIM
Phase: Clinical Trials
▹ REMED BRAINSTIM produces magnetic stimulation devices such as the Brainstim-100 and Musfit. These devices generate time-varying magnetic fields to induce electrical currents in targeted areas of the cerebral cortex. This stimulation is used to treat a variety of neurological and psychiatric conditions. This technology has been approved by the FDA for safety and efficacy in treating depression, smoking cessation, anxiety disorders, obsessive-compulsive disorder, and insomnia.
▹▶ REMED has successfully miniaturized a hospital-grade brain stimulation system into a convenient home device. The new version, approved by the Korean Ministry of Food and Drug Safety, is lightweight (less than 4 kg), cost-effective (costs less than $1,000 to manufacture), and features a user-friendly design with a helmet-style applicator. This design allows for easy integration with digital therapies and expands access to noninvasive brain stimulation for patients outside of clinical settings.
 
SEVEN POINT ONE
Phase: Already Commercialized
▹ AlzWIN is an AI-powered voice recognition assessment tool. Clinically validated for early dementia detection, it provides results in approximately one minute via smartphone, PC, or landline. This internationally recognized and adopted tool has helped identify over 12,000 dementia patients through extensive screening programs.
▹▶ AlzWIN addresses the challenges of early dementia detection by providing a fast, accessible, and clinically validated cognitive health assessment. Many people experience cognitive decline without realizing it, and traditional screening methods can be time-consuming, expensive, or inaccessible.
 
Voinosis
Phase: Clinical Trial
▹ Brain Guard Doctor, Voice Check are AI-powered digital healthcare solutions that utilize voice analysis to screen for hearing loss and monitor early cognitive changes in asymptomatic individuals before the onset of dementia. This solution enables proactive intervention and prevention for B2C and B2B customers.
▹▶ It detects the early stages of dementia, addressing issues of delayed diagnosis, diagnostic accuracy, and accessibility. This digital healthcare solution empowers patients and caregivers at home, shifting authority away from hospitals. By predicting and preventing the onset of dementia, it revolutionizes dementia care and represents a significant step forward toward proactive healthcare.

 

| Radiology
Current Market Landscape | The diagnostic imaging services market is valued at $140 billion by 2024. The US radiology market is expected to grow due to advancements in MRI technology, diverse applications of MRI in the medical field, and expanding insurance coverage for diagnostic imaging.

Radiology contributes significantly to the early and accurate diagnosis of diseases. The increasing prevalence of cancer and cardiovascular disease is expected to drive demand for diagnostic imaging devices.

Integrating AI into diagnostic imaging offers numerous benefits, including improved diagnostic accuracy, improved workflow efficiency, and personalized patient care.
 
METLiT
Phase: Clinical Trials
▹ The MRS Analytics AI tool enhances magnetic resonance spectroscopy (MRS) by using deep learning to quantify metabolites and reduce uncertainty, making this diagnostic method more accessible and user-friendly. This technology automates data analysis and has shown clinical promise in areas such as tumor IDH mutation detection and mitochondrial dysfunction.
▹▶ The MRS Analytics AI tool improves accessibility and user experience through automated analysis and productization. Deep learning and AI-based methods improve several aspects of traditional MRS, including reducing scan times and extracting information from raw MRS data
. PROMEDIUS Phase: Product Launch (MFDS Approval) ▹ Osteo Signal is the world's first AI software to assist in the diagnosis of osteoporosis based on chest X-ray images. It provides early screening of asymptomatic osteoporosis, providing opportunities for treatment and preventing devastating fractures.  ▹▶ Osteoporotic hip fractures are devastating, with a one-year mortality rate of up to 21%. Early detection of osteoporosis is crucial for its prevention.  However, DXA scans, the current standard for diagnosis, are very limited in accessibility worldwide. Promedius utilizes chest X-rays, the world's most frequently taken, to screen for osteoporosis risk early and provide timely treatment opportunities, thereby preventing fatal fractures and saving lives. Silla System Stage: Clinical Trial ▹ Pine-DX is an AI medical device that analyzes spinal X-rays to diagnose scoliosis. The device detects spinal alignment, calculates the Cobb angle, and assesses spinal rotation using the Nash-Maw scale. It also assesses bone maturity in the pelvic region, providing comprehensive information to support scoliosis diagnosis and progression prediction. ▹▶ Most AI medical tools are built for a single disease, forcing healthcare institutions to implement multiple, disparate systems. Each system requires separate integration, training, and costs. Pine-DX addresses this segmentation problem by providing a general-purpose skeletal AI framework that automates anatomical measurements across a variety of conditions. Its adaptability to various imaging environments reduces retraining and customization, streamlining implementation and reducing costs for healthcare providers.
 
 
| Additional innovative companies in various fields

AI for Pet 
Category: Pre-diagnosis screening | Stage: Already commercialized
▹ AI for Pet (TTcare) analyzes photos taken with a smartphone to provide real-time, personalized health information for pets with 95% accuracy.
▹▶ TTcare Vet solves the problem of veterinary hospitals lacking accessible, scalable, and objective early health screening tools. Many hospitals struggle to detect early clinical signs due to time constraints, inconsistent technician training, and lack of specialized equipment or knowledge. TTcare Vet uses AI to enable veterinarians to examine eyes, skin, ears, teeth, and gait conditions using only a smartphone, enabling faster triage, preventive care, and increased hospital efficiency.

Bio Design Lab Co., Ltd.
Oncology | Stage: Already Commercialized
▹ Safe and effective viral vectors for cell and gene therapy, including CAR-T, minimizing the risk of integration into oncogenes.
▹▶ Reduced the risk of secondary cancer occurrence and enhanced gene delivery and expression of T cells and NK cells.
 
Carenation Inc.
Healthcare Platform | Stage: Already Commercialized
▹ Carenation is a leading digital healthcare platform that connects caregivers with patients with acute and chronic diseases through a smart care matching solution. This platform reduces problems such as sudden cancellations, unannounced absences, and additional compensation claims.
▹▶ Traditional caregiving services often experience delays in fee settlement and liability insurance processing due to a lack of real-time supervision. Carenation solves these problems by digitizing caregiver workflows, daily payments, automating insurance processing, and AI-based care matching based on structured service data. Dentis Dental
 
Dentis
| Stage: Already commercialized
▹ SERAFIN is AI-based software that assesses a patient's suitability for clear aligners, generates a treatment plan, and designs customized dental models and appliances. Its proprietary 3D printer capable of dual-material printing and multi-layer mesh sheets enable efficient and high-quality aligner production.
▹▶ Existing clear aligner sheet materials are prone to delamination after long-term oral use. Dentis' multi-layer sheets increase the interlayer bonding strength to reduce delamination and enhance durability and intraoral stability. The improved material improves continuous orthodontic force by 15% during the wear period. 

 

Four-O LAB OCTA-SELL. [Photo = Four-O LAB]

Four-O LAB
Gastroenterology | Stage: Already commercialized, ready for market launch
▹ The OCTA-SELL disposable endoscope sterilizer generates hypochlorite directly within the device to sterilize endoscopes. The disinfectant is disposable and is disposed of in the drain after a single use. It is equipped with an ultrasonic vibrator to thoroughly sterilize the endoscopes.
▹▶ OCTA-SELL prevents corrosion during endoscope sterilization.
 
Hicare.net Inc.
Smart Healthcare Platform | Stage: Already commercialized
▹ Hicare.net's RMS (Remote Monitoring Service) platform integrates remote patient monitoring (RPM) and chronic disease management (CCM) with AI-based chronic disease monitoring. It helps Medicare patients improve their health, reduce hospital visits, and lower healthcare costs with free monitoring devices. For healthcare providers, it improves the quality and outcomes of care while increasing revenue through insurance reimbursement.
▹▶ Patients measure their vital signs at home or in long-term care facilities and transmit the data in real time. The platform uses intelligent algorithms to track adherence to care plans and converts it into structured data. This enables automatic trend analysis of patient health and the generation of alerts for potential warning signs. Considering that the primary user of the RMS platform is elderly patients, the intuitive and simple interface was designed, resulting in significantly increased patient engagement.

 

Indream Healthcare 
Multi-Pharmacy | Stage: Already Commercialized
▹ Indream Healthcare is a clinical decision support system that provides fast, accurate, and scalable prescription insights to doctors and patients worldwide using OCR technology. Its flagship product, InDream MediSupport, collects real-time medication data from patients' current prescriptions and delivers actionable insights to healthcare providers, significantly improving medication safety.
▹▶ Indream Healthcare's innovation addresses the challenges of unsafe, inefficient, and fragmented medication management. It reduces medication errors, improves multi-drug therapy oversight, streamlines clinical workflows, enables data integration across systems, supports personalized prescribing, enhances remote patient management, and consolidates medical records into a single, secure platform.
 
MCK Tech Co., Ltd.
Urology | Phase: Clinical Trials
▹ MCK Tech is developing a graphene biosensor diagnostic platform that accurately measures sodium and potassium levels in urine for chronic disease management. Leveraging graphene, it can selectively measure sodium concentrations even in the presence of ionic impurities, white blood cells, and red blood cells.
▹▶ MCK Tech enables patients with renal failure or chronic diseases to easily measure ion concentrations in urine anytime, anywhere. MCK Tech's graphene sensor platform is expected to expand beyond current ion concentration measurements to include cancer and virus diagnosis.

MedySapiens
Rare genetic diseases, cancer, infectious diseases | Phase: Ready for launch
▹ An AI-based genome analysis company specializing in the diagnosis of genetic and infectious diseases. Key products include MedySOL, a genome data generation reagent kit, and MedyCVi, AI software for genetic mutation analysis and disease association identification. Using AI and genomic information from a small blood sample, the company quickly and accurately diagnoses rare diseases in newborns.
While modern testing methods struggle to detect root causes, MediSapiens' NGS-based targeted sequencing provides the solution. Processing time has been reduced from 4-6 weeks to 3 days. Blood sampling for premature or low-birth-weight infants in the NICU can be extremely painful, requiring only a single drop of blood instead of a tube. Genetic mutation analysis and interpretation time has been reduced from over 10 hours per case to under 30 minutes, making it over 20 times more efficient.
 
Microt Inc.
Ophthalmology | Stage: FDA/CE/KFDA Approved
▹ A-Stream is a glaucoma implant designed to maintain aqueous humor drainage and is Korea's first minimally invasive glaucoma surgery (MIGS) device. It is compact, measuring 6 mm in length and 100 μm in inner diameter.
▹▶ MIGS is increasingly being adopted due to its simple surgical procedure and low risk of complications. Currently, MIGS devices on the market are relatively easy to operate, but often fail to produce satisfactory surgical results. A-Stream provides effective postoperative intraocular pressure reduction with a simple surgical technique.
 
MINDSAI
Psychiatry | Stage: Already commercialized
▹ Minds.NAVI is a psychiatric assessment software that integrates psychological indicators and biomarkers (salivary hormones) to screen depressed patients at high risk for suicide. It comprehensively assesses depressive symptoms, suicide risk, and key protective and vulnerability factors for depression.
▹▶ Minds.NAVI can enhance individuals' psychological well-being and reduce the socioeconomic burden of depression and suicide risk. Early screening and appropriate patient assessment increase treatment success rates. While many barriers exist between the onset and diagnosis of depression, Minds.NAVI improves accessibility, identifies high-risk groups for depressive disorders, and links them to the healthcare system, thereby increasing treatment rates.
 
Nemesis Co., Ltd.
Biosignal Processing | Stage: Already commercialized
▹We develop low-power, intelligent biosignal processing system-on-chip (SoC) for medical devices. We combine advanced analog design, biosensor technology, and machine learning to provide accurate and customizable solutions for digital healthcare.
▹▶ Nemesis helps medical device manufacturers improve biosignal processing and data transmission capabilities. This enables customers to develop devices with improved sensing capabilities, smaller size, and longer battery life.  Rznomics Inc. RNA Therapeutics | Stage: In Development ▹ Rznomics' trans-splicing ribozyme platform edits RNA for oncology and central nervous system diseases. Currently, five R&D pipelines are in development: RZ-001 (hepatocellular carcinoma/glioblastoma), RZ-002 (glioblastoma), RZ-003 (Alzheimer's disease), RZ-004 (retinitis pigmentosa), and RZ-005 (degenerative diseases).  ▹▶ It targets molecules that are difficult to treat with drugs at the RNA level, effectively reduces target gene expression while inducing therapeutic gene expression, and allows editing/correction of various mutations with a single treatment. WisMedical Co., Ltd. Cardiopulmonary | Stage: Clinical Trial ▹ Tedream™ is a soft, wearable medical device that continuously monitors cardiopulmonary and physiological signals. The first service focuses on home sleep studies, and the second service provides in-hospital and post-discharge monitoring. ▹▶ Tedream™ enhances patient comfort with three patch-type devices. It is relatively simple to install and allows real-time monitoring in the hospital and at home, helping with post-discharge management and monitoring of critically ill patients.

Rznomics Inc.

RNA Therapeutics | Stage: In Development

▹ Rznomics' trans-splicing ribozyme platform edits RNA for oncology and central nervous system diseases. Currently, five R&D pipelines are in development: RZ-001 (hepatocellular carcinoma/glioblastoma), RZ-002 (glioblastoma), RZ-003 (Alzheimer's disease), RZ-004 (retinitis pigmentosa), and RZ-005 (degenerative diseases). 

▹▶ It targets molecules that are difficult to treat with drugs at the RNA level, effectively reduces target gene expression while inducing therapeutic gene expression, and allows editing/correction of various mutations with a single treatment.

 

WisMedical Co., Ltd.

Cardiopulmonary | Stage: Clinical Trial

▹ Tedream™ is a soft, wearable medical device that continuously monitors cardiopulmonary and physiological signals. The first service focuses on home sleep studies, and the second service provides in-hospital and post-discharge monitoring.

▹▶ Tedream™ enhances patient comfort with three patch-type devices. It is relatively simple to install and allows real-time monitoring in the hospital and at home, helping with post-discharge management and monitoring of critically ill patients.
 

 

 

 

 

 

 

Article published: July 30, 2025, 5:00 AM

Last modified on July 31, 2025, at 8:54 AM

Reporter's name Suzy Lim

https://www.fortunekorea.co.kr/news/articleView.html?idxno=49204